The aim of the Consorcio Centro de Investigación Biomédica en Red, M.P, CIBER, a public research consortium set up at the initiative of the Instituto de Salud Carlos III (ISCIII) is to further excellence research in Biomedicine and Health Sciences done in the National Health System and in the Science and Technology System. To this end, efforts and interdisciplinary and multi-institutional research are combined with a preferential dedication of financial resources around knowledge networks formed by centres and research groups reporting to different administrations and public and private institutions.


The NMR Biomedical Applications Group (GABRMN, acronym for the Catalan name of the group) from Autonomous University of Barcelona (UAB) is the CIBER-BBN group CB06/01/0010, being part of CIBER since its foundation in 2006. The group belongs to the Biochemistry and Molecular Biology Department of the Biosciences Faculty, and it is directed by Prof. Carles Arús. Prof. Arús is full professor at UAB with more than 160 publications and a long track record in the field of acquisition, processing and interpretation of magnetic resonance-based data. Major present interest in brain tumors, their diagnosis and follow-up based in “in vivo” metabolomics. The GABRMN-UAB group also counts with the participation of Dr. Ana Paula Candiota, senior CIBER-BBN researcher ascribed to UAB, with 18+ years of postdoctoral expertise in preclinical glioblastoma models, and MR-based noninvasive metabolomics analyses of therapy response. She is also project leader in MICINN and REDES funded projects. The group performance is also participated by Dr. Mª Margarida Julià-Sapé, assistant professor (“professor agregat”) at UAB and leading the Molecular Imaging DataLab group (MIDALab). Her background is related to MR data processing and postprocessing, decision support systems and bioinformatics, being project leader in FIS and EU-ITN funded projects.


The GBT-CTB group is part of CIBER-BBN and has extensive experience in the fields of Bioengineering, Biomaterials and Nanomedicine. Its main interests and research lines are focused on: Quantitative analysis and processing of multimodal medical images, development of new segmentation methodologies and biomarker definition; Medical data analysis with survival analysis in different cancer typologies, federated learning for data analysis in COVID-19, and definition of novel personalized treatments in lung cancer; Diabetes by developing closed-loop artificial pancreas systems and implementing Artificial Intelligence techniques for health outcome prediction and patient characterization; Neuro-rehabilitation and brain health through personalized intelligent coaching, digital phenotyping, and data analysis; Clinical simulation for training and quality assessment of surgical procedures; Telemedicine systems through mHealth technologies in cancer, HIV, endocrinological diseases and adherence to treatment; Bioinstrumentation and nanomedicine through the development of novel techniques for anti-tumoral therapies, development of new nanoparticles, and development of technical tools for mobility in blind people; Aging and maintenance of functional autonomy, cognitive assessment with gamified interactive stimulation, and smart systems to prevent and reverse functional decline; Biomaterials and regenerative engineering for tendon/ligament repair, precise drug delivery, cell therapies, and improvements in biocompatibility and sensing resolution.

The Biomedical Engineering Group of the University of Valladolid (GIB-UVa)

The Biomedical Engineering Group of the University of Valladolid (GIB-UVa) is a multidisciplinary research group in Spain. It belongs to the Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), It is a Consolidated Research Unit (UIC-060) of Junta de Castilla y León and a Recognized Research Group (GIR) of the University of Valladolid. GIB-UVa is mainly formed by Engineers and Medical Doctors specialized in various areas, such as pneumology, neurology, neurophysiology, psychiatry and ophthalmology. The objectives of this group include: (i) Research and development of biomedical signals analysis methods (EEG, MEG, EMG, oxygen saturation, etc) to help in the diagnosis of pathologies like Alzheimer’s and Parkinson’s diseases, schizophrenia, epilepsy or obstructive sleep apnoea (OSA); (ii) Research and development of image analysis techniques in ophthalmology to help in the diagnosis of visual conditions such as diabetic retinopathy or age-related macular degeneration; and (iii) Design and development of assistance systems for disabled people or people with speech and language impairments by means of Brain Computer Interface (BCI). The group members participating in EUCAIM are: Roberto Hornero Sánchez, María García Gadañón, Gonzalo C. Gutiérrez Tobal and Roberto Romero Oraá.

The Biomedical Neuroengineering group of the Bioengineering Institute of Miguel Hernández University

The Biomedical Neuroengineering group of the Bioengineering Institute of Miguel Hernández University combines biomedicine with the physical sciences and engineering to develop new treatments and devices that can be applied to enhance the lives of people that are affected by visual impairments more effectively. The fundamental research interest of the group is focused on the development of new strategies and innovative solutions to communicate with the brain that can be applied to enhance the quality of life of people who are affected by visual impairments. The group has extensive experience in brain imaging, particularly MRI, fMRI, DTI, and magnetic resonance spectroscopy.

Biomedical Image Technology

Biomedical Image Technology (BIT-UPM) is a research group of the Universidad Politecnica de Madrid and CIBERBBN whose main objective is the research of new technological solutions to real clinical or biological problems, especially with the aim of optimising diagnosis and treatment. The group has experience in advanced biomedical image processing for segmentation, alignment, feature extraction and automatic calculation of biomarkers using image processing and artificial intelligence techniques. These techniques have been developed in different projects related to lung cancer, glioblastoma, breast cancer, primary tumours and liver metastases by processing information from medical images (CT, MR) and histopathological images and integrating them with clinical data. The group has a strong network of industrial, technical and clinical collaborators at an international level. Full professors Andrés Santos Lleó and María J Ledesma Carbayo and staff members Juan E Ortuño-Fisac and Eva Rojas will be the people from the group more involved in the EUCAIM project.

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

March 14, 10:00-11:30 aM CET



Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.